AGWCA
LGND icon

Annis Gardner Whiting Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$799 – 853
2026
Q1 		$799 Hold
4
– – ﹤0.01% 1172
2025
Q4 		$757 Hold
4
– – ﹤0.01% 1082
2025
Q3 		$709 Hold
4
– – ﹤0.01% 1039
2025
Q2 		$455 Buy
+4
New +$428 ﹤0.01% 1200

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's LGND Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 4 shares — an estimated $799 sold.

Annis Gardner Whiting Capital Advisors first reported a position in LGND in Q2 2025 and held it in 4 quarters. The position peaked at $799 in Q1 2026. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 4 Ligand Pharmaceuticals shares in Q2 2026, an estimated $799.
  • Annis Gardner Whiting Capital Advisors first reported a position in Ligand Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Annis Gardner Whiting Capital Advisors's Ligand Pharmaceuticals position peaked at $799 in Q1 2026.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.